IMMURON LIMITED - Announcements

1.45%

7.0¢

Market Cap $18.77M

Healthcare Biotechnology

Immuron Limited is an Australia-based biopharmaceutical company focused on developing and... Immuron Limited is an Australia-based biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. It operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects performed in Australia and the United States. Hyperimmune products segment is engaged in Travelan and Protectyn activities which occur predominantly in Australia, the United States and Canada. Its flagship products consist of Travelan and Protectyn. Travelan is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveler’s diarrhea and is sold in pharmacies throughout Australia. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. Its clinical programs include Travelan (IMM-124E), IMM-529, and CampETEC.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

IMC	Appendix 4D and Interim Financial Report - Dec 2013	PRICE SENSITIVE	28/02/14	1.21MB	Share
IMC	Renounceable Rights Issue - Closure, Acceptances & Shortfall	PRICE SENSITIVE	26/02/14	78.95KB	Share
IMC	Immuron to Raise $9.66M via Fully Underwritten Rights Issue	PRICE SENSITIVE	22/01/14	102.11KB	Share
IMC	Trading Halt	PRICE SENSITIVE	20/01/14	78.62KB	Share
IMC	Immuron's Travelan Approved for Marketing in Canada	PRICE SENSITIVE	13/11/13	84.88KB	Share
IMC	US FDA Clears Another IND for Phase 2 Trial for IMM-124E	PRICE SENSITIVE	08/11/13	141.85KB	Share
IMC	Immuron Allowed Travelan Patent in the United States	PRICE SENSITIVE	23/10/13	81.35KB	Share
IMC	Appendix 4E - Preliminary Final Report	PRICE SENSITIVE	30/08/13	1.08MB	Share
IMC	Immuron to Adopt a New Direct-to-Wholesalers Sales Model	PRICE SENSITIVE	04/06/13	91.71KB	Share
IMC	Prospectus -Underwritten Renounceable Rights Issue	PRICE SENSITIVE	27/03/13	431.81KB	Share
IMC	Fully Underwritten Renounceable Rights Issue	PRICE SENSITIVE	27/03/13	26.91KB	Share
IMC	Trading Halt	PRICE SENSITIVE	25/03/13	105.37KB	Share
IMC	Further Positive Results on Clostridium Difficile Program	PRICE SENSITIVE	04/03/13	411.22KB	Share
IMC	Half Year Results and Accounts 31 December 2012	PRICE SENSITIVE	28/02/13	798.04KB	Share
IMC	Resignation of Joe Baini as Director and CEO.	PRICE SENSITIVE	22/02/13	112.98KB	Share
IMC	CLOSTRIDIUM DIFFICILE Project Update	PRICE SENSITIVE	17/12/12	148.67KB	Share
IMC	Positive Results from Colostridium Difficile Program	PRICE SENSITIVE	19/09/12	166.13KB	Share
IMC	Travelan Distribution Agreement for China and Taiwan	PRICE SENSITIVE	12/09/12	330.38KB	Share
IMC	Results for Announcement to the Market	PRICE SENSITIVE	31/08/12	16.18KB	Share
IMC	Influenza program for Swine Flu	PRICE SENSITIVE	15/08/12	148.08KB	Share
IMC	NIH Grant for Immuron's IMM 124E for Alcholic Fatty Liver	PRICE SENSITIVE	06/08/12	148.68KB	Share
IMC	Prospectus for Bonus Issue of Options	PRICE SENSITIVE	09/07/12	2.98MB	Share
IMC	Finalisation of Share Purchase Plan	PRICE SENSITIVE	18/06/12	113.45KB	Share
IMC	Travelan application - Canada	PRICE SENSITIVE	04/06/12	165.25KB	Share
IMC	Travelan Distribution in Singapore, Malaysia and Brunei	PRICE SENSITIVE	14/05/12	64.86KB	Share
IMC	Travelan licensed to Thailand, Hong Kong, Cambodia, Vietnam	PRICE SENSITIVE	10/05/12	145.91KB	Share
IMC	Agreement with Synlait Milk for Hyperimmune requirements	PRICE SENSITIVE	07/05/12	143.97KB	Share
IMC	Capital Raising announcement	PRICE SENSITIVE	23/04/12	47.08KB	Share
IMC	Reinstatement to Official Quotation	PRICE SENSITIVE	23/04/12	25.32KB	Share
IMC	Suspension from Official Quotation	PRICE SENSITIVE	20/04/12	67.4KB	Share
IMC	Trading Halt Request	PRICE SENSITIVE	18/04/12	40.85KB	Share
IMC	Trading Halt	PRICE SENSITIVE	18/04/12	77.54KB	Share
IMC	Immuron appoints Joe Baini Chief Executive Officer	PRICE SENSITIVE	05/03/12	151.65KB	Share
IMC	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/12	209.35KB	Share
IMC	Immuron and Monash University to Collaborate on C. difficile	PRICE SENSITIVE	31/01/12	214.22KB	Share
IMC	Immuron finalises funding facility	PRICE SENSITIVE	16/01/12	379.62KB	Share
IMC	IND cleared for NASH/Fatty Liver Phase IIb trials	PRICE SENSITIVE	10/01/12	583.94KB	Share
IMC	Research agreement with Harvard Medical School	PRICE SENSITIVE	16/12/11	97.48KB	Share
IMC	Travelan Licence Deal with Paladin Labs Inc. Canada	PRICE SENSITIVE	29/11/11	86.77KB	Share
IMC	Immuron submits NASH IND Application with FDA	PRICE SENSITIVE	07/11/11	72.29KB	Share
IMC	Non-Renounceable Issue Shortfall	PRICE SENSITIVE	04/11/11	53.22KB	Share
IMC	Offer Document for Non-Renounceable Rights Issue	PRICE SENSITIVE	31/08/11	418.69KB	Share
IMC	Results for Announcement to the Market	PRICE SENSITIVE	31/08/11	13.71KB	Share
IMC	Immuron's Novel Influenza Product Advances to Human Trial	PRICE SENSITIVE	29/08/11	33.6KB	Share
IMC	Phase 2B NASH trial on track following meeting with FDA	PRICE SENSITIVE	22/08/11	57.03KB	Share
IMC	Notice of Non-Renounceable Rights Issue	PRICE SENSITIVE	17/08/11	27.35KB	Share
IMC	Travelan discovered to affect E.coli O104 outbreak in Europe	PRICE SENSITIVE	26/07/11	52.56KB	Share
IMC	HIV Program proceeds to Expanded Human Trial	PRICE SENSITIVE	21/07/11	72.34KB	Share
IMC	Shareholder Update	PRICE SENSITIVE	01/06/11	310.21KB	Share
IMC	Immuron Granted FDA pre-IND Meeting re Phase 2b Trial	PRICE SENSITIVE	19/04/11	60.23KB	Share
IMC	Immurons Influenza Program Shows Effectiveness in Trials	PRICE SENSITIVE	17/03/11	171.05KB	Share
IMC	Important Progress in HIV Prevention Project	PRICE SENSITIVE	08/03/11	6.27MB	Share
IMC	Immuron Granted Key Patent for Influenza Product	PRICE SENSITIVE	01/03/11	166.42KB	Share
IMC	Half Yearly Report and Accounts	PRICE SENSITIVE	01/03/11	916.57KB	Share
IMC	Australian Sales of Travelan expected to Increase	PRICE SENSITIVE	24/02/11	168.58KB	Share
IMC	Appointment of New Chief Executive Officer	PRICE SENSITIVE	17/01/11	151.33KB	Share
IMC	Preliminary Final Report	PRICE SENSITIVE	31/08/10	212.73KB	Share
IMC	Successful Results from NASH Clinical Trial	PRICE SENSITIVE	23/08/10	468.1KB	Share
IMC	Immuron and Nycomed expand 'Travelan' into other territories	PRICE SENSITIVE	11/06/10	235.5KB	Share
IMC	Collaboration with Nycomed on Influenza Product	PRICE SENSITIVE	21/05/10	232.74KB	Share
IMC	Strong Interest in Immuron NASH Product	PRICE SENSITIVE	17/05/10	47.59KB	Share
IMC	Nycomed Licenses Immuron's Travelan Product	PRICE SENSITIVE	06/05/10	48.77KB	Share
IMC	Pre-clinical Trials for Influenza Prevention Product	PRICE SENSITIVE	04/05/10	46.35KB	Share
IMC	HIV Phase 2 trial completed. Final results expected mid year	PRICE SENSITIVE	19/04/10	239.48KB	Share
IMC	Shareholder Share Purchase Plan	PRICE SENSITIVE	19/04/10	321.08KB	Share
IMC	Phase II clinical trial for Metabolic Syndrome and NASH	PRICE SENSITIVE	29/03/10	239.6KB	Share
IMC	Half Yearly Report and Accounts	PRICE SENSITIVE	25/02/10	945.25KB	Share
IMC	Commencement of Phase 2 Clinical Trials - Metabolic Syndrome	PRICE SENSITIVE	16/12/09	80.72KB	Share
IMC	Chairman and CEO presentations and Nycomed A'ment	PRICE SENSITIVE	23/11/09	217.45KB	Share
IMC	Significant Progress in Treatment of Metabolic Syndrome	PRICE SENSITIVE	11/11/09	138.27KB	Share
IMC	Preliminary Final Report	PRICE SENSITIVE	31/08/09	571.72KB	Share
IMC	Influenza Drug Development Program	PRICE SENSITIVE	13/08/09	122.16KB	Share
IMC	Influenza Drug Development Program	PRICE SENSITIVE	11/08/09	426.93KB	Share
IMC	Update on Influenza research program	PRICE SENSITIVE	03/08/09	190.77KB	Share
IMC	GRAS status of Immuron Hyperimmune Oral Antibody formulation	PRICE SENSITIVE	20/04/09	333.96KB	Share
IMC	Agreement with Hadasit Medical Centre	PRICE SENSITIVE	20/04/09	5MB	Share
IMC	Commencement of Travelan sales in USA	PRICE SENSITIVE	25/03/09	174.53KB	Share
IMC	Half Year Report Appendix 4D	PRICE SENSITIVE	26/02/09	311.67KB	Share
IMC	Clinical Trial Approved	PRICE SENSITIVE	13/01/09	60.51KB	Share
IMC	US Distribution Agreement and Strategic Investment	PRICE SENSITIVE	15/12/08	923.28KB	Share

IMCAppendix 4D and Interim Financial Report - Dec 2013
28/02/14	PRICE SENSITIVE	1.21MB	Share
IMCRenounceable Rights Issue - Closure, Acceptances & Shortfall
26/02/14	PRICE SENSITIVE	78.95KB	Share
IMCImmuron to Raise $9.66M via Fully Underwritten Rights Issue
22/01/14	PRICE SENSITIVE	102.11KB	Share
IMCTrading Halt
20/01/14	PRICE SENSITIVE	78.62KB	Share
IMCImmuron's Travelan Approved for Marketing in Canada
13/11/13	PRICE SENSITIVE	84.88KB	Share
IMCUS FDA Clears Another IND for Phase 2 Trial for IMM-124E
08/11/13	PRICE SENSITIVE	141.85KB	Share
IMCImmuron Allowed Travelan Patent in the United States
23/10/13	PRICE SENSITIVE	81.35KB	Share
IMCAppendix 4E - Preliminary Final Report
30/08/13	PRICE SENSITIVE	1.08MB	Share
IMCImmuron to Adopt a New Direct-to-Wholesalers Sales Model
04/06/13	PRICE SENSITIVE	91.71KB	Share
IMCProspectus -Underwritten Renounceable Rights Issue
27/03/13	PRICE SENSITIVE	431.81KB	Share
IMCFully Underwritten Renounceable Rights Issue
27/03/13	PRICE SENSITIVE	26.91KB	Share
IMCTrading Halt
25/03/13	PRICE SENSITIVE	105.37KB	Share
IMCFurther Positive Results on Clostridium Difficile Program
04/03/13	PRICE SENSITIVE	411.22KB	Share
IMCHalf Year Results and Accounts 31 December 2012
28/02/13	PRICE SENSITIVE	798.04KB	Share
IMCResignation of Joe Baini as Director and CEO.
22/02/13	PRICE SENSITIVE	112.98KB	Share
IMCCLOSTRIDIUM DIFFICILE Project Update
17/12/12	PRICE SENSITIVE	148.67KB	Share
IMCPositive Results from Colostridium Difficile Program
19/09/12	PRICE SENSITIVE	166.13KB	Share
IMCTravelan Distribution Agreement for China and Taiwan
12/09/12	PRICE SENSITIVE	330.38KB	Share
IMCResults for Announcement to the Market
31/08/12	PRICE SENSITIVE	16.18KB	Share
IMCInfluenza program for Swine Flu
15/08/12	PRICE SENSITIVE	148.08KB	Share
IMCNIH Grant for Immuron's IMM 124E for Alcholic Fatty Liver
06/08/12	PRICE SENSITIVE	148.68KB	Share
IMCProspectus for Bonus Issue of Options
09/07/12	PRICE SENSITIVE	2.98MB	Share
IMCFinalisation of Share Purchase Plan
18/06/12	PRICE SENSITIVE	113.45KB	Share
IMCTravelan application - Canada
04/06/12	PRICE SENSITIVE	165.25KB	Share
IMCTravelan Distribution in Singapore, Malaysia and Brunei
14/05/12	PRICE SENSITIVE	64.86KB	Share
IMCTravelan licensed to Thailand, Hong Kong, Cambodia, Vietnam
10/05/12	PRICE SENSITIVE	145.91KB	Share
IMCAgreement with Synlait Milk for Hyperimmune requirements
07/05/12	PRICE SENSITIVE	143.97KB	Share
IMCCapital Raising announcement
23/04/12	PRICE SENSITIVE	47.08KB	Share
IMCReinstatement to Official Quotation
23/04/12	PRICE SENSITIVE	25.32KB	Share
IMCSuspension from Official Quotation
20/04/12	PRICE SENSITIVE	67.4KB	Share
IMCTrading Halt Request
18/04/12	PRICE SENSITIVE	40.85KB	Share
IMCTrading Halt
18/04/12	PRICE SENSITIVE	77.54KB	Share
IMCImmuron appoints Joe Baini Chief Executive Officer
05/03/12	PRICE SENSITIVE	151.65KB	Share
IMCHalf Yearly Report and Accounts
28/02/12	PRICE SENSITIVE	209.35KB	Share
IMCImmuron and Monash University to Collaborate on C. difficile
31/01/12	PRICE SENSITIVE	214.22KB	Share
IMCImmuron finalises funding facility
16/01/12	PRICE SENSITIVE	379.62KB	Share
IMCIND cleared for NASH/Fatty Liver Phase IIb trials
10/01/12	PRICE SENSITIVE	583.94KB	Share
IMCResearch agreement with Harvard Medical School
16/12/11	PRICE SENSITIVE	97.48KB	Share
IMCTravelan Licence Deal with Paladin Labs Inc. Canada
29/11/11	PRICE SENSITIVE	86.77KB	Share
IMCImmuron submits NASH IND Application with FDA
07/11/11	PRICE SENSITIVE	72.29KB	Share
IMCNon-Renounceable Issue Shortfall
04/11/11	PRICE SENSITIVE	53.22KB	Share
IMCOffer Document for Non-Renounceable Rights Issue
31/08/11	PRICE SENSITIVE	418.69KB	Share
IMCResults for Announcement to the Market
31/08/11	PRICE SENSITIVE	13.71KB	Share
IMCImmuron's Novel Influenza Product Advances to Human Trial
29/08/11	PRICE SENSITIVE	33.6KB	Share
IMCPhase 2B NASH trial on track following meeting with FDA
22/08/11	PRICE SENSITIVE	57.03KB	Share
IMCNotice of Non-Renounceable Rights Issue
17/08/11	PRICE SENSITIVE	27.35KB	Share
IMCTravelan discovered to affect E.coli O104 outbreak in Europe
26/07/11	PRICE SENSITIVE	52.56KB	Share
IMCHIV Program proceeds to Expanded Human Trial
21/07/11	PRICE SENSITIVE	72.34KB	Share
IMCShareholder Update
01/06/11	PRICE SENSITIVE	310.21KB	Share
IMCImmuron Granted FDA pre-IND Meeting re Phase 2b Trial
19/04/11	PRICE SENSITIVE	60.23KB	Share
IMCImmurons Influenza Program Shows Effectiveness in Trials
17/03/11	PRICE SENSITIVE	171.05KB	Share
IMCImportant Progress in HIV Prevention Project
08/03/11	PRICE SENSITIVE	6.27MB	Share
IMCImmuron Granted Key Patent for Influenza Product
01/03/11	PRICE SENSITIVE	166.42KB	Share
IMCHalf Yearly Report and Accounts
01/03/11	PRICE SENSITIVE	916.57KB	Share
IMCAustralian Sales of Travelan expected to Increase
24/02/11	PRICE SENSITIVE	168.58KB	Share
IMCAppointment of New Chief Executive Officer
17/01/11	PRICE SENSITIVE	151.33KB	Share
IMCPreliminary Final Report
31/08/10	PRICE SENSITIVE	212.73KB	Share
IMCSuccessful Results from NASH Clinical Trial
23/08/10	PRICE SENSITIVE	468.1KB	Share
IMCImmuron and Nycomed expand 'Travelan' into other territories
11/06/10	PRICE SENSITIVE	235.5KB	Share
IMCCollaboration with Nycomed on Influenza Product
21/05/10	PRICE SENSITIVE	232.74KB	Share
IMCStrong Interest in Immuron NASH Product
17/05/10	PRICE SENSITIVE	47.59KB	Share
IMCNycomed Licenses Immuron's Travelan Product
06/05/10	PRICE SENSITIVE	48.77KB	Share
IMCPre-clinical Trials for Influenza Prevention Product
04/05/10	PRICE SENSITIVE	46.35KB	Share
IMCHIV Phase 2 trial completed. Final results expected mid year
19/04/10	PRICE SENSITIVE	239.48KB	Share
IMCShareholder Share Purchase Plan
19/04/10	PRICE SENSITIVE	321.08KB	Share
IMCPhase II clinical trial for Metabolic Syndrome and NASH
29/03/10	PRICE SENSITIVE	239.6KB	Share
IMCHalf Yearly Report and Accounts
25/02/10	PRICE SENSITIVE	945.25KB	Share
IMCCommencement of Phase 2 Clinical Trials - Metabolic Syndrome
16/12/09	PRICE SENSITIVE	80.72KB	Share
IMCChairman and CEO presentations and Nycomed A'ment
23/11/09	PRICE SENSITIVE	217.45KB	Share
IMCSignificant Progress in Treatment of Metabolic Syndrome
11/11/09	PRICE SENSITIVE	138.27KB	Share
IMCPreliminary Final Report
31/08/09	PRICE SENSITIVE	571.72KB	Share
IMCInfluenza Drug Development Program
13/08/09	PRICE SENSITIVE	122.16KB	Share
IMCInfluenza Drug Development Program
11/08/09	PRICE SENSITIVE	426.93KB	Share
IMCUpdate on Influenza research program
03/08/09	PRICE SENSITIVE	190.77KB	Share
IMCGRAS status of Immuron Hyperimmune Oral Antibody formulation
20/04/09	PRICE SENSITIVE	333.96KB	Share
IMCAgreement with Hadasit Medical Centre
20/04/09	PRICE SENSITIVE	5MB	Share
IMCCommencement of Travelan sales in USA
25/03/09	PRICE SENSITIVE	174.53KB	Share
IMCHalf Year Report Appendix 4D
26/02/09	PRICE SENSITIVE	311.67KB	Share
IMCClinical Trial Approved
13/01/09	PRICE SENSITIVE	60.51KB	Share
IMCUS Distribution Agreement and Strategic Investment
15/12/08	PRICE SENSITIVE	923.28KB	Share

REFRESH

First 2

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 7.0¢		Change 0.001(1.45%)		Mkt cap ! $18.77M

Open	High	Low	Value	Volume
6.8¢	7.0¢	6.8¢	$16.84K	244.6K

Buyers (Bids)

No.	Vol.	Price($)
1	10000	6.8¢

Sellers (Offers)

Price($)	Vol.	No.
7.0¢	148417	1

View Market Depth

No.	Vol.	Price($)
1	10000	0.068
2	10000	0.067
1	75000	0.066
2	87000	0.065
1	15858	0.063

Price($)	Vol.	No.
0.070	148417	1
0.072	46048	2
0.073	1750	1
0.074	7500	1
0.075	23346	2

Last trade - 16.10pm 11/09/2025 (20 minute delay)


Last 6.8¢		Change 0.001 ( 2.86 %)
Open	High	Low	Volume
6.8¢	6.8¢	6.7¢	43964
Last updated 12.33pm 11/09/2025 ?

IMC (ASX) Chart

IMMURON LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available